This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
Marcos Castanheira Alegria
Advertisement
Marcos Castanheira Alegria is R&D director at Hypera Pharma.
Articles by Marcos Castanheira Alegria
Advertisement
Latest Updated Articles
Brazilian Regulation of Biosimilar Products: What Is Important to KnowPublished: September 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
